IS3945A - Aðferð til framleiðslu á ediksýruafleiðum - Google Patents

Aðferð til framleiðslu á ediksýruafleiðum

Info

Publication number
IS3945A
IS3945A IS3945A IS3945A IS3945A IS 3945 A IS3945 A IS 3945A IS 3945 A IS3945 A IS 3945A IS 3945 A IS3945 A IS 3945A IS 3945 A IS3945 A IS 3945A
Authority
IS
Iceland
Prior art keywords
production
acetic acid
acid derivatives
derivatives
acetic
Prior art date
Application number
IS3945A
Other languages
English (en)
Inventor
Porter Barry
David Eldred Colin
Anderson Kelly Henry
Russell Wheatcroft James
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919124221A external-priority patent/GB9124221D0/en
Priority claimed from GB929201052A external-priority patent/GB9201052D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS3945A publication Critical patent/IS3945A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS3945A 1991-11-14 1992-11-13 Aðferð til framleiðslu á ediksýruafleiðum IS3945A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919124221A GB9124221D0 (en) 1991-11-14 1991-11-14 Chemical compounds
GB929201052A GB9201052D0 (en) 1992-01-16 1992-01-16 Chemical compounds

Publications (1)

Publication Number Publication Date
IS3945A true IS3945A (is) 1993-05-15

Family

ID=26299862

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3945A IS3945A (is) 1991-11-14 1992-11-13 Aðferð til framleiðslu á ediksýruafleiðum

Country Status (10)

Country Link
EP (2) EP0542363A3 (is)
JP (1) JPH07501063A (is)
CN (1) CN1073169A (is)
AP (1) AP330A (is)
AU (1) AU2915892A (is)
IL (1) IL103746A0 (is)
IS (1) IS3945A (is)
MX (1) MX9206541A (is)
TW (1) TW221996B (is)
WO (1) WO1993010091A2 (is)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW257757B (is) * 1993-03-03 1995-09-21 Boehringer Mannheim Gmbh
DE4309285A1 (de) * 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
DK0691959T3 (da) * 1993-03-29 1999-04-26 Zeneca Ltd Heterocykliske derivater som blodpladeaggregations-inhibitorer
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
EP0690847A1 (en) * 1993-03-29 1996-01-10 Zeneca Limited Heterocyclic compounds as platelet aggregation inhibitors
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
JPH06340619A (ja) * 1993-05-03 1994-12-13 Bristol Myers Squibb Co グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
JP4039684B2 (ja) 1994-05-04 2008-01-30 バイエル・アクチエンゲゼルシヤフト 置換された芳香族チオカルボン酸アミド類及びその除草剤としての使用
USRE39263E1 (en) * 1994-05-04 2006-09-05 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
RU2156763C2 (ru) * 1994-07-15 2000-09-27 Мейдзи Сейка Кабусики Кайся Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и способ лечения или профилактики тромботических заболеваний
EP0801650A4 (en) * 1994-12-22 1998-05-06 Smithkline Beecham Corp FIBRINOGEN RECEPTOR ANTAGONISTS
ZA951822B (en) * 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
FR2728901B1 (fr) * 1994-12-28 1997-03-28 Sanofi Sa Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
IL116893A (en) * 1995-02-10 2000-02-29 Yamanouchi Pharma Co Ltd Piperazine derivatives and pharmaceutical compositions containing them
AU4633296A (en) * 1995-02-10 1996-08-27 Yamanouchi Pharmaceutical Co., Ltd. Novel benzamidine derivatives and medicinal composition thereof
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
GB9511989D0 (en) * 1995-06-13 1995-08-09 Glaxo Group Ltd Chemical compounds
AU6318896A (en) * 1995-07-06 1997-02-05 Japan Tobacco Inc. Benzamidoxime derivatives and medicinal use thereof
JP2000510445A (ja) * 1996-03-30 2000-08-15 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のオキサゾリジン誘導体、その製法及び当該化合物を含有する医薬製剤
TW403745B (en) * 1996-05-30 2000-09-01 Yamanouchi Pharma Co Ltd Novel substituted -amidinobenzene derivative and pharmaceutical compositions thereof
WO1997049698A1 (en) * 1996-06-21 1997-12-31 Glaxo Group Limited Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
AR008245A1 (es) * 1996-06-21 1999-12-29 Glaxo Group Ltd Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
DE19643331A1 (de) * 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19652919A1 (de) * 1996-12-19 1998-06-25 Solvay Pharm Gmbh Piperazinophenyl- und Piperazinophenyloxy-carbonsäure-Derivate sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AR013693A1 (es) * 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
AU1692399A (en) * 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Aromatic compounds having cyclic amino or salts thereof
WO1999050249A2 (en) 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
WO2000017163A1 (en) * 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6204282B1 (en) 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
DE60209736T2 (de) 2001-07-02 2006-11-02 Astrazeneca Ab Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
JP2008530216A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Cxcr3アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物
AU2006214378A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
WO2006091428A2 (en) 2005-02-16 2006-08-31 Schering Corporation Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity
CN101189238A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
CA2598458A1 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
EP1919909B1 (en) * 2005-08-31 2013-08-21 Armetheon, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
PE20071144A1 (es) 2006-03-21 2008-01-10 Schering Corp COMPUESTOS HETEROCICLICOS DE PIRIDINA SUSTITUIDA COMO ANTAGONISTAS DEL RECEPTOR 3 DE a-QUIMIOCINA (CXCR3)
AR061975A1 (es) 2006-07-14 2008-08-10 Schering Corp Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3
DE102007038250A1 (de) 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
US11046685B2 (en) * 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095239B (en) * 1981-02-27 1985-03-06 Torii & Co Ltd Novel amidine compounds
US4433152A (en) * 1981-05-25 1984-02-21 Nippon Chemiphar Co., Ltd. Amidinopiperidine derivatives
PT84171B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados das n alfa-aril-sulfonilamiminoacil-p- -amidinofenil-alaninamidas, bem como dos seus derivados de sintese e das composicoes farmaceuticas que os contem
GB9122016D0 (en) * 1991-10-16 1991-11-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP0612313A1 (en) 1994-08-31
EP0542363A3 (en) 1993-07-14
IL103746A0 (en) 1993-04-04
WO1993010091A2 (en) 1993-05-27
AP9200447A0 (en) 1993-01-31
CN1073169A (zh) 1993-06-16
AP330A (en) 1994-03-30
AU2915892A (en) 1993-06-15
MX9206541A (es) 1993-04-01
WO1993010091A3 (en) 1993-06-24
JPH07501063A (ja) 1995-02-02
EP0542363A2 (en) 1993-05-19
TW221996B (is) 1994-04-01

Similar Documents

Publication Publication Date Title
NO943318L (no) Fremgangsmåte for fremstilling av eddiksyre
IS3915A (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3914A (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3873A (is) Hliðstæð aðferð til framleiðslu á kristölluðum oxaþíólan afleiðum
IS3871A (is) Hliðstæðar aðferðir til framleiðslu á Quinuclidine afleiðum
IS4201A (is) Aðferð til framleiðslu á Benzofuran afleiðum
NO975916D0 (no) Indiumkatalysert karbonyleringsprosess for fremstilling av eddiksyre
IS3994A (is) Hliðstæð aðferð til framleiðslu á indole afleiðum
NO993543D0 (no) Fremgangsmåte for fremstilling av eddiksyre
PT87355A (pt) Process for the production of folinic acid
IS1708B (is) Hliðstæð aðferð til framleiðslu á vatnsuppleysanlegum kamptóþesín afleiðum
NO891650L (no) Fremgangsmaate ved fremstilling av pyridonkarboksylsyrederivater.
FI104075B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-karboksitienyylikarbamoyylipyrrolidin-4-yylitiokarbapeneemi-3-karboksyylihappojohdannaisten valmistamiseksi
IS3589A7 (is) Aðferð við framleiðslu á efnasambandinu Indenoindoles I
PT88545A (pt) Process for the manufacture of benzimidazoline-2-oxo-1-carboxylic acid derivative compounds
IS4079A (is) Milliefni til framleiðslu á súbstitúeruðum bensimidasólum
NO975296D0 (no) Fremgangsmåte for fremstilling av karboksylsyrederivater
HU913280D0 (en) Process for the production of 8-chloro-kinoline derivatives
FI896284A7 (fi) Menetelmä karboksyylihappojohdannaisten valmistamiseksi
FI905930A7 (fi) Menetelmä uusien, farmakologisesti käyttökelpoisten bispilokarpiinihapon esterijohdannaisten valmistamiseksi
FI913300A7 (fi) Menetelmä aryylisubstituoitujen propionihappoesterien valmistamiseksi
FI920373A7 (fi) Menetelmä aminokarboksyylihappoesterien valmistamiseksi
IS4707A (is) Aðferð til framleiðslu á díoxóazabísýklóhexönum
FI881032A7 (fi) Menetelmä N-asetyyli-3 -fluorineuramiinihappojohdannaisten valmistamiseksi.
ITRM930260A0 (it) Procedimento per la produzione di acidi perfluoroetercarbossilici.